Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity.
Purity:
>99.0%
CAS Number:
[2227102-46-5]
Target:
Drug-Linker Conjugates for ADC
* VAT and and shipping costs not included. Errors and price changes excepted